

# Market Announcement

18 August 2022

---

## Invex Therapeutics Ltd (ASX: IXC) – Trading Halt

### Description

The securities of Invex Therapeutics Ltd ('IXC') will be placed in trading halt at the request of IXC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 22 August 2022 or when the announcement is released to the market.

### Issued by

**Jenita Iyalu**

Adviser, Listings Compliance (Perth)

Barbara Lim  
Adviser, Listings Compliance (Perth)  
ASX Compliance Pty Ltd  
Level 40, Central Park, 152 -158 St Georges Terrace  
PERTH WA 6000

By Email: [barbara.lim@asx.com.au](mailto:barbara.lim@asx.com.au); [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

**18 August 2022**

Dear Barbara


**TRADING HALT**

Invex Therapeutics Limited (ACN 632 145 334) (Company) hereby requests a trading halt on its securities, effective from the commencement of trading on Thursday, 18 August 2022, and provides the following information in relation to ASX Listing Rule 17.1:

1. the Company expects to make a material announcement to the market in relation to a formal response received from the US Food and Drug Administration ("FDA") in relation to an Investigational New Drug Application filed by the Company to commence the IIH EVOLVE Phase III clinical trial in the United States ("FDA Response");
2. the Company wishes the trading halt to last until the earlier of commencement of normal trading on Monday, 22 August 2022 and the Company making an announcement about the FDA Response;
3. the Company is not aware of any reason why the trading halt should not be granted; and
4. the Company is not aware of any other information that is necessary to inform the market about the trading halt.

If you have any queries, please do not hesitate to contact me on 0412 830 308.

Yours faithfully



Narelle Warren  
Company Secretary